TPST today

$0.38-$0.00 (-0.42%)close Nov 13, 2026

Trend

DailyDowntrend (confirmed)

4 hourStrong Bearish

1 hourSymmetric Triangle

15 minStrong Bearish

5 minStrong Bearish

Daily trend turns up above $0.56

Key levels

Resistance$0.56

Resistance$0.50

Support$0.34

About Tempest Therapeutics

Tempest Therapeutics is a biotechnology firm in the clinic stage that works on engineered immune cell treatments and oral medicines for tumors and immune disorders. Its programs include cell-based candidates aimed at blood cancers and solid tumors, plus two pill-form drugs, one for liver cancer and one for a rare inherited condition that raises gastrointestinal cancer risk. The company is based in the United States and carries out some development work in China through partners.

Based on the company's 10-K filed Mar 30, 2026.

Nasdaq · Healthcare

Tempest Therapeutics, Inc. (TPST)

$0.38-0.00 (-0.29%)

REDUCEGrade: DRisk: HIGH

1D 5D1M1Y 5Y MaxSign up for all timeframes

High0.39

Low0.36

Open0.38

Volume128K

Avg Vol176K

VWAP0.38

30d High0.79

30d Low0.36

30d Chg-51.82%

See full chart with real-time data

What Is the Price Target for TPST?

SEPT Low Target

$0.00

SEPT Mid Target

$0.00

SEPT High Target

$0.00

Analyst Consensus

$0.00

Current: $0.37Upside: +0.0%Confidence: 20%Method: No Coverage

Is TPST a Buy or Sell Right Now?

Investability Score

REDUCE12-18 months

News summary · last 30 days

Nov 13▲ UpEarningsContract2 articles

Tempest Therapeutics reported a third-quarter loss of $0.21 per share, narrower than the $0.32 loss analysts expected, a positive earnings surprise. The company also exercised an option to license Senlang's CD7-targeted cell therapy platform, which uses an in-body lentiviral delivery approach. Despite these bullish developments, the stock closed at $0.38, down 0.29% on the day, with a trading range of $0.36 to $0.39 on volume of 127,748 shares. The news signals potential upside from both the better-than-expected financials and the expanded pipeline, though the muted price reaction suggests the market may have already priced in some of this optimism.

Critical news

Oct 23HIGHPrice move report

Oct 21HIGHPrice move report

AI-Powered Trading Signals

Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for TPST.

Start Free Trial →

Is TPST Overvalued or Undervalued?

Valuation Verdict

N/A

Methods Used

N/A

Fair Value

$N/A

Moat Score

NONE

1/9

Piotroski Score

-24.0

Altman Z-Score

What Is Smart Money Doing with TPST?

Insider Signal

NEUTRAL

1 buys / 0 sells (90d)

Congress Signal

NEUTRAL

0 buys / 0 sells (90d)

Institutional

N/A

Short Squeeze Risk

LOW

Signal: NEUTRAL

Track Smart Money Across 4,000+ Stocks

Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.

See All Smart Money Signals →

TPST Growth Story

Revenue YoY

N/A%

3yr Revenue CAGR

N/A%

EPS Growth YoY

67.54%

FCF Growth YoY

19.9%

Revenue Trend

UNKNOWN

Dark Pool Trades for TPST

PREVIEW

SEPT Investing tracks real-time dark pool institutional trades for TPST, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.

Time	Price	Size	Value	Side
20:54:26	$0.38	10,000	$$4K	SELL
20:54:17	$0.38	10,000	$$4K	SELL
19:53:56	$0.39	1,200	$$466	BUY
19:53:26	$0.38	7,000	$$3K	SELL
19:30:13	$0.38	1,000	$$382	SELL

5 dark pool trades shown · $$11K preview volume

Real-time institutional flow, block trades, and net positioning

See all dark pool activity

Full AI Research Report

SEPT's Trading AI has generated a free, downloadable PDF research report for Tempest Therapeutics, Inc. (TPST) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.

Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (1 articles analyzed), and SEC filing intelligence...

AI-Powered Trading Signals.

Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.

Try SEPT Free for 7 Days →

TPST — frequently asked questions

What is TPST stock price today?

Tempest Therapeutics, Inc. (TPST) is at $0.38, down 0.42% (-$0.00) at the Nov 13, 2026 close.

Why is TPST stock down today?

Nov 13, 2026: Tempest Therapeutics reported a third-quarter loss of $0.21 per share, narrower than the $0.32 loss analysts expected, a positive earnings surprise. The company also exercised an option to license Senlang's CD7-targeted cell therapy platform, which uses an in-body lentiviral delivery approach.

Did TPST beat earnings?

TPST last reported on Aug 13, 2026: EPS -$0.34 vs -$0.30 expected — a miss of 13.3%.

Does TPST pay a dividend?

TPST does not currently pay a dividend.

What are TPST support and resistance levels?

Support: $0.34. Resistance: $0.50, $0.56, $0.74.

What are insiders doing with TPST?

Insider activity: NEUTRAL, 1 buys and 0 sells in the last 90 days.

What is the latest news on TPST?

Nov 13, 2026: Tempest Therapeutics, Inc. filed a report on a major company event (Form 8-K) · Nov 13, 2026: Tempest Therapeutics posts narrower quarterly loss than expected · Nov 13, 2026: Tempest Therapeutics takes license option on Senlang cell therapy platform